CRISPR CAS9
Reducing the pace of metastasis in ovarian cancer
Recently, we have investigated the role of TNNC-1 on EMT in ovarian cancer cells using CRISPR/Cas9 genome editing technology. Ovarian cancer is one of the leading causes of death from gynecological malignancies. A majority (75%) of patients is diagnosed at the advanced phase with widespread peritoneal dissemination, as early stage ovarian cancer is usually asymptomatic. Consequently, its prognosis is poor, with a 5-year survival rate less than 50%. To date, the molecular mechanism of ovarian cancer metastasis is still unknown.
Troponin C type 1 (TNNC1) is commonly overexpressed in ovarian cancer. However, the biological implications of TNNC1 overexpression on ovarian cancer malignization and its related mechanism remain unknown. To elucidate these implications, we knocked out the TNNC1 gene in TNNC1-overexpressing SKOV-3-13 ovarian cancer cells using CRISPR/Cas-9 technology and observed the changes in metastatic phenotypes and related molecular pathways.
In conclusion, TNNC1 overexpression contributes to the metastatic behavior of ovarian cancer by perturbation of EMT and actin microfilaments. Our results provide a better understanding of the detailed molecular mechanism of ovarian cancer metastasis associated with TNNC1 overexpression.
The research work were published in the BBRC journal. For more information on the research details click https://doi.org/10.1016/j.bbrc.2021.02.021